1
Clinical Trials associated with EBV CAR-T Cell(Fudan University) / RecruitingEarly Phase 1IIT Clinical Study on the Safety and Efficacy of EBV CAR-T /TCR-T Cells in the Treatment of Recurrent / Refractory EBV Positive Nasopharyngeal Carcinoma
This study was a single-arm, open-label, "3 + 3" dose-escalation Exploratory research. The patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group. The EBV CAR-T-treated group received three progressively increasing dose levels (3.0 × 106 cells/kg, 9.0 × 106 cells/kg, 1.5 × 107 cells/kg) of EBV CAR-T-cell therapy; The EBV TCR-T-cell group received three progressively increasing doses (5.0 × 106 cells/kg, 1.5 × 107 cells/kg, 3.0 × 107 cells/kg) of EBV TCR-T-cell therapy.
100 Clinical Results associated with EBV CAR-T Cell(Fudan University)
100 Translational Medicine associated with EBV CAR-T Cell(Fudan University)
100 Patents (Medical) associated with EBV CAR-T Cell(Fudan University)
100 Deals associated with EBV CAR-T Cell(Fudan University)